Published by Global Banking & Finance Review®
Posted on August 7, 2025
2 min readLast updated: January 22, 2026
Add as preferred source on GoogleWegovy and Mounjaro sales in India doubled in July, reflecting increased demand for anti-obesity drugs. Wegovy launched in June, while Mounjaro's sales have surged since March.
By Rishika Sadam and Kashish Tandon
HYDERABAD (Reuters) -Sales of Danish drugmaker Novo Nordisk's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday.
Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world's most populous nation.
Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data showed.
Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees.
"Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a statement.
In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes.
Mounjaro's sales have soared 15 times since March, when the drug was launched in India.
($1 = 87.6790 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala)
Sales of Wegovy more than doubled to 5,000 units or 70 million rupees in July.
Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees.
Rybelsus has created a strong prescriber base for Wegovy, which may help in its promotion.
Mounjaro was launched in India in March, and its sales have soared 15 times since then.
Both Wegovy and Mounjaro are anti-obesity drugs that help control blood sugar and slow digestion.
Explore more articles in the Finance category
